Optimizing BCG therapy

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 3, 2009, Pages 325-328

  O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

BCG; Bladder cancer

Indexed keywords

4 AMINOMETHYLBENZOIC ACID; AMINOCAPROIC ACID; BCG VACCINE; CYCLOOXYGENASE 2 INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERFERON; INTERLEUKIN 2;

BCG VACCINATION; BLADDER CANCER; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; CYSTECTOMY; DISEASE FREE INTERVAL; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME;

BCG VACCINE; HUMANS; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC DISEASES;

EID: 65349116510     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.10.024     Document Type: Review

References (40)

1. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 Update. J Urol 178 (2007) 2314-2330
2. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
3. Takashi M., Wakai K., Hattori T., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ. Int Urol Nephrol 33 (2002) 41-47
4. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1001
5. Gallagher B.L., Joudi F.N., Maymí J.L., et al. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 71 (2008) 297-301
6. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1640
7. Verrini G., Brausi M., Gavioli M., et al. Low efficacy of intravesical BCG immunotherapy in elderly patients with intermediate-high risk Ta-T1 transitional cell carcinoma of the bladder: Long term experience of a single institution. J Urol Suppl 175 (2006) 271
8. Kohjimoto Y, Iba A, Kuramoto T, et al. Impact of age on outcome of patients with superficial bladder cancer. Proceedings of the Societe' Internationale d'Urologie meeting, Cape Town, South Africa, November 2006.
9. Herr H.W. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology 70 (2007) 65-68
10. Jakse G., Algaba F., Malmstrom P.U., et al. A second-look TUR in T1 transitional cell carcinoma: Why?. Eur Urol 45 (2004) 539-546
11. Grimm M.-O., Steinhoff C., Simon X., et al. Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J Urol 170 (2003) 433-437
12. Jahnson S., Wiklund F., Duchek M., et al. Results of second look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 39 (2005) 206-210
13. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174 (2005) 2134-2137
14. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 (2007) 75-79
15. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
16. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin vs. mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
17. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 686-687
18. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-92
19. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
20. Martinez-Pineiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
21. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
22. Ojea A., Nogueira J.L., Solsona E., et al. A multicenter, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27 mg) vs. very low-dose bacillus Calmette-Guerin (13.5 mg) vs. mitomycin C. Eur Urol 52 (2007) 1398-1406
23. Morales A., Nickel J.C., and Wilson J.W. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 147 (1992) 1256-1258
24. Bassi P., Spinadin R., Carando R., et al. Modified induction course: A solution to side-effects?. Eur Urol 37 Suppl 1 (2000) 31-32
25. Andius P., Fehrling M., and Holmäng S. Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96 (2005) 1290-1293
26. van der Meijden A.P., Brausi M., Zambon V., et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166 (2001) 476-481
27. Colombel M., Saint F., Chopin D., et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled multicenter study. J Urol 176 (2006) 935-939
28. Luo Y., Chen X., Downs T.M., et al. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162 (1999) 2399-2405
29. Dovedi S.J., Kirby J.A., Atkins H., et al. Cyclooxygenase-2 inhibition: A potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 174 (2005) 332-337
30. Luo Y., Chen X., and O'Donnell M.A. Role of Th1 and Th2 cytokines in BCG-induced IFN- γ production: Cytokine promotion and simulation of BCG effect. Cytokine 21 (2003) 17-26
31. O'Donnell M.A. The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol 15 (1997) 512-517
32. P'ng K.B., Walsh M.D., Seymour G.J., et al. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer. Aust NZ J Surg 63 (1993) 127-130
33. Hudson M.A., Yuan J.J., Catalona W.J., et al. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144 (1990) 1362-1364
34. Witjes J.A., van der Meijden A.P., Doesburg W., et al. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group. Eur Urol 23 (1993) 366-370
35. Shen Z.J., Wang Y., Ding G.Q., et al. Study on enhancement of fibronectin-mediated bacillus Calmette-Guerin attachment to urinary bladder wall in rabbits. World J Urol 25 (2007) 525-529
36. Pan C.W., Shen Z.J., and Ding G.Q. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study. J Urol 179 (2008) 1307-1312
37. Jewett M.A.S., Nieder A.M., Brausi M., et al. T1 Urothelial Carcinoma of the Bladder. In: Soloway, Carmack, and Khoury (Eds). Bladder Tumors (2006), Health Publications Ltd, Paris 189-218
38. Cheng L., Cheville J.C., Neumann R.M., et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85 (1999) 2469-2474
39. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164 (2000) 680-684
40. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299